News & Updates
Filter by Specialty:
Dapagliflozin cuts HbA1c in paediatric T2D
Dapagliflozin reduced HbA1c by 1.03 percentage points more than placebo in children and adolescents with type 2 diabetes (T2D), while saxagliptin showed no significant reduction vs placebo in the phase III T2NOW trial presented at EASD 2023.
Dapagliflozin cuts HbA1c in paediatric T2D
17 Oct 2023
First-line therapies for advanced NSCLC improve survival, QoL
Clinical trials on first-line therapies for advanced or metastatic nonsmall cell lung cancer (NSCLC) from 2010 to 2020 have reported better survival and a steady improvement in quality of life (QoL) among patients, according to the results of a systematic review.
First-line therapies for advanced NSCLC improve survival, QoL
16 Oct 2023
Behavioural interventions improve screening colonoscopy uptake
Use of behavioural interventions, specifically multicomponent and patient navigation interventions, helps increase the uptake of colonoscopy for colorectal cancer (CRC) screening, reveals a study.
Behavioural interventions improve screening colonoscopy uptake
16 Oct 2023
Social deprivation tied to higher glaucoma risk
Personal poverty, as defined by not driving a personal vehicle to the appointment, and neighbourhood-level poverty appear to contribute to higher rates of screening positive for glaucoma or suspected glaucoma, suggests a study.
Social deprivation tied to higher glaucoma risk
16 Oct 2023
Finerenone confers cardiorenal benefits in Chinese CKD, T2D patients
In the subgroup analysis of the phase III FIGARO-DKD trial, the selective nonsteroidal mineralocorticoid receptor antagonist finerenone conferred cardiorenal benefits in Chinese patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). The findings were consistent with that observed in the overall cohort.
